OPT News and Press, Opthea Limited From 07/14/23

(NewsDirect) Ocean Power Technologies (OPT) CEO Philipp Stratmann joined Natalie Stoberman from the Proactive studios to discuss the company's growth strategy in the field of ocean intelligence. Stratmann said OPT has successfully pivoted into the ocean intelligence industry, offering...

Podium presentation on the pharmacokinetics and safety of OPT-302 in retinal vascular diseases Participation in “Live From ASRS” virtual KOL discussion on market trends and new treatments in wet AMD hosted by Oppenheimer & Co. MELBOURNE, Australia, July 13, 2023 ...

MONROE TOWNSHIP, N.J., July 12, 2023 (GLOBE NEWSWIRE) -- Ocean Power Technologies, Inc. ("OPT" or "the Company") (NYSE American: OPTT), today announced financial results for its fiscal fourth quarter (“4Q23”) and full-year ended April 30, 2023 (“FY23”). Highlights incl...

MELBOURNE, Australia, July 10, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today  the  resignation of Dr. Joel Naor, Chief Medic...

MONROE TOWNSHIP, N.J., June 15, 2023 (GLOBE NEWSWIRE) -- Ocean Power Technologies, Inc. ("OPT" or "the Company") (NYSE American: OPTT), a leader in innovative and cost-effective low-carbon marine power, data, and service solutions, today announced that it will report its fiscal 2023 fourth quarte...

MELBOURNE, Australia, June 08, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, is pleased to announce the appointment of Mr. Anshul Thakral as a Non-Exe...

Optiva and lifecell Named as a Nominee in TM Forum's 16th Annual Excellence Awards Canada NewsWire TM Forum's prestigious awards recognize the organizations making a significant contribution to the acceleration of digital transformation throughout the industry as top telecom ope...

MELBOURNE, Australia, May 25, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today that Dr. Megan Baldwin, the Company’s Chief Executi...

MELBOURNE, Australia, May 17, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today that Elemer Piros, Senior Biotechnlogy Analyst at EF Hutto...

MELBOURNE, Australia, May 08, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today that Timothy E. Morris, the Company’s Chief Financi...